Cargando…

Integration of endocrine therapy with targeted agents

Detalles Bibliográficos
Autor principal:	Johnston, Stephen RD
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2008
Materias:	Short Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2614846/ https://www.ncbi.nlm.nih.gov/pubmed/19128434 http://dx.doi.org/10.1186/bcr2180

Ejemplares similares

Are current drug development programmes realising the full potential of new agents? The scenario
por: Johnston, Stephen RD
Publicado: (2009)

Pharmacogenetics and pharmacogenomics of endocrine agents for breast cancer
por: Ingle, James N
Publicado: (2008)

Endocrine and targeted treatments for breast cancer
por: Hudis, Clifford A
Publicado: (2007)

Current and future choices in endocrine therapy
por: Ellis, Matthew
Publicado: (2007)

Do classical oestrogen markers predict for clinical response to endocrine therapy?
por: Miller, William R
Publicado: (2007)

Markers of endocrine sensitivity
por: Hayes, Daniel F
Publicado: (2008)

Identification and mechanisms of endocrine resistance
por: Miller, William R
Publicado: (2008)

Do BIG1-98 and ZOFAST demand a change in guidelines for endocrine therapy?
por: Smith, Ian E
Publicado: (2009)

Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer
por: Leary, Alexandra F, et al.
Publicado: (2007)

Evaluation of biological agents targeted at early-stage disease
por: Guix, Marta, et al.
Publicado: (2008)

Neoadjuvant endocrine therapy for luminal breast cancer treatment: a first-choice alternative in times of crisis such as the COVID-19 pandemic
por: Martí, Covadonga, et al.
Publicado: (2020)

Anaphylactic risks associated with immunobiological agents in asthma therapy
por: Baddini-Martinez, José, et al.
Publicado: (2023)

Donepezil + chromone + melatonin hybrids as promising agents for Alzheimer’s disease therapy
por: Pachón-Angona, Irene, et al.
Publicado: (2019)

Synthesis and biological assessment of KojoTacrines as new agents for Alzheimer’s disease therapy
por: Dgachi, Youssef, et al.
Publicado: (2018)

Endocrine correlates of male breast cancer risk: a case-control study in Athens, Greece
por: Petridou, E, et al.
Publicado: (2000)

A novel MEN1 pathogenic variant in an Italian patient with multiple endocrine neoplasia type 1
por: Corsello, Andrea, et al.
Publicado: (2020)

New targets for therapy in breast cancer: Farnesyltransferase inhibitors
por: Head, Julia, et al.
Publicado: (2004)

Update on endocrine aspects of breast cancer: Report from the 23(rd) San Antonio Breast Cancer Symposium, San Antonio, Texas, USA, 6-9 December 2000
por: Johnston, Stephen RD
Publicado: (2001)

Adjuvant Abemaciclib Combined with Endocrine Therapy: Efficacy Results in monarchE Cohort 1
por: Toi, Masakazu, et al.
Publicado: (2022)

A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer
por: Shamash, J, et al.
Publicado: (2008)

Dual-target anti-Alzheimer’s disease agents with both iron ion chelating and monoamine oxidase-B inhibitory activity
por: Mi, Zhisheng, et al.
Publicado: (2019)

Controversies in breast cancer: the mammalian target of rapamycin as a target for breast cancer therapy
por: Di Cosimo, Serena
Publicado: (2009)

Dual therapy with renally adjusted lamivudine and dolutegravir: a switch strategy to manage comorbidity and toxicity in older, suppressed patients?
por: Tan, M, et al.
Publicado: (2019)

Angiogenesis - still a worthwhile target for breast cancer therapy?
por: Lord, Simon, et al.
Publicado: (2010)

Tailored targeted therapy for all: a realistic and worthwhile objective?
por: Lønning, Per Eystein
Publicado: (2009)

Breast tumour stroma is a prognostic indicator and target for therapy
por: Howell, Anthony, et al.
Publicado: (2009)

New Benzofuran Derivatives as an Antioxidant Agent
por: Rindhe, S. S., et al.
Publicado: (2010)

Synthesis and Evaluation of Flavanones as Anticancer Agents
por: Murti, Y., et al.
Publicado: (2014)

Mindfulness-integrated cognitive behavioral therapy: Is it effective on stress coping strategies in women with multiple sclerosis?
por: Montazeri, Sahar, et al.
Publicado: (2022)

Tailored targeted therapy for all: a realistic and worthwhile objective against
por: Pritchard, Kathleen I
Publicado: (2009)

Bullous Pemphigoid-like Eruption Triggered by Targeted Therapy for Metastatic Melanoma
por: ERIKSSON, Hanna, et al.
Publicado: (2020)

Are current drug development programmes realising the full potential of new agents? Introduction to Sessions 7 and 8
por: Johnston, Stephen RD
Publicado: (2009)

Bdellovibrio bacteriovorus : A future antimicrobial agent?
por: Harini, K., et al.
Publicado: (2013)

Vorticella sp: Prospective Mosquito Biocontrol Agent
por: Patil, Chandrashekhar Devidas, et al.
Publicado: (2016)

Immune's-boosting agent: Immunomodulation potentials of propolis
por: Al-Hariri, Mohammed
Publicado: (2019)

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies
por: Grünwald, V, et al.
Publicado: (2011)

Graphene-based contrast agents for photoacoustic and thermoacoustic tomography()
por: Lalwani, Gaurav, et al.
Publicado: (2013)

Pharmacological evaluation of embelin - chitosan nanoparticles as an antidiabetic agent
por: Maanvizhi, Saba, et al.
Publicado: (2022)

Nitroimidazooxazoles(#) Part xxiv, Search for Antileishmanial Agents: 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles as Potential Antileishmanial Agents
por: Shashiprabha,, et al.
Publicado: (2014)

Transmission of droplet-conveyed infectious agents such as SARS-CoV-2 by speech and vocal exercises during speech therapy: preliminary experiment concerning airflow velocity
por: Giovanni, Antoine, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i0itktejg3arcirdim9cb3er39